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Hearing loss has been described in patients undergoing 
chemotherapy, given the ototoxic nature of these drugs. An 
audiological investigation is relevant in such cases. Aim: to 
assess audibility thresholds at high frequencies in individu-
als with cancer that was treated successfully with cisplatin 
and its associations, to verify possible hearing loss as a side 
effect of therapy. Site and date of the study: Campinas, Sao 
Paulo, in 2006. Material and Method: Ten volunteers aged 
between 5 and 27 years were assessed by a clinical history, 
otoscopy, and conventional and high frequencies audiometry 
in this clinical and experimental study. Results: A kappa 
coefficient statistical analysis revealed significant differences 
between ears in 50% of 14 frequencies that were evaluated. 
Eight participants presented hearing losses, which started 
at 1 kHz, increasing markedly at 6 kHz and above. Fisher’s 
Exact Test revealed a significant association only with the 
dose and the right ear at high frequencies. Conclusion: It 
is possible that the hearing loss detected in this study is at 
least partially due to the ototoxicity of antineoplastic drugs; 
such loss may occur even after treatment is interrupted. We 
suggest that a protocol for audiological follow-up of patients 
undergoing chemotherapy should be created.
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INTRODUCTION
Cisplatin is a potent anticancer drug that is widely 
used in the treatment of advanced cancer in adult and 
children. One of its side effects is ototoxicity, which rela-
ted directly with the dose and the administration route; a 
single high dose may affect hearing more intensely than 
the same amount given in fractionated doses.1,2 Cisplatin 
is used against various cancer types in humans, such as 
testicle and ovarian cancer, head and neck cancer, lung 
cancer and germinative cell cancer. This drug is effective 
in chemotherapy when given by the intraperitoneal or 
endovenous routes, and has a therapeutic potential in 
many malignancies, particularly those mentioned above.3 
Given a certain blood concentration, toxic substances may 
reach the organ of Corti and the sensorineural epithelia 
of the posterior labyrinth by means of the labyrinthic 
fluids. Ototoxic drugs result in cochlear and/or vestibular 
symptoms. These symptoms may progress slowly and in-
sidiously, even after the drug has been withdrawn; there 
is generally a direct relation between the dose and the 
severity of otological injury. The longer a toxic substance 
remains in the organism, the more severe will its harmful 
effect be, although there may be individual differences in 
the response to such agents, as well as the part played by 
a family history of hearing loss, noise sensitivity, among 
others.4
Individuals using chemotherapy, for instance with 
cisplatin, could avoid degeneration of the organ of Corti if 
ototoxicity were monitored and/or detected early.5 Some 
authors argue that high frequency pure tone audiometry 
helps detect ototoxicity due to cisplatin, and that frequen-
cies of 12,000 Hz and 14,000 Hz are especially important. 
Hearing data may be altered by changes in the dosage of 
drugs or in treatment methods.1 High frequency pure tone 
audiometry investigates cochlear baseline responses, asses-
sing audition from 8,000 to 20,000 Hz, depending on the 
clinical audiometer that is used.6,7 It is currently considered 
as a relevant tool for the early diagnosis of sensorineural 
hearing loss, which usually begins at higher frequencies.6-8 
Investigation of patients undergoing clinical therapy with 
ototoxic drugs has underlined the important role of high 
frequency audiometry in monitoring hearing loss.1,5,9
Further studies have shown that high frequencies 
are needed for discriminating between consonants and for 
recognizing speech; individuals with hearing loss of any 
degree at these frequencies find it difficult to understand 
speech in noisy environments.10
The main use of high frequency audiometry is 
in monitoring the audition of patients in which hearing 
losses are suspected; the main conditions are ototoxicity, 
sequelae of otitis media, chronic renal failure, presbya-
cusis, assessment of auditory processing, investigation of 
auditory changes in families with inherited hearing loss, 
and monitoring of individuals that are frequently exposed 
to noise.11,12
Cancer
Cancer is a range of disease in various sites and of 
different morphological types, which have in common two 
main biological features: uncontrolled cell growth and the 
ability to extend beyond the tissue of origin. Variability 
exists relative to the stage in which each cancer is detected 
by available diagnostic methods.13
Germ cell tumors, also known as teratomas, endo-
dermal sinus tumors or embryogenic carcinomas, originate 
from the aforementioned germ cells, and follow an ab-
normal path. When cells in these tumors begin to divide, 
tumors are formed with parts of hair, teeth, skin and others. 
In different cases, germ cells originate malignancies, beha-
ving aggressively. Such germ cell tumors may occur at any 
age in childhood; testicles, ovaries, the vagina, the sacrum 
and coccyx (lower vertebrae) are frequently involved, as 
well as less frequent sites such as the head and neck, the 
liver and the brain. These tumors, however, are less fre-
quent compared to leukemia and brain tumors.14
Neuroblastomas are about 8% of cancers in children 
aged below 15 years. This is a solid tumor that develops 
in nervous tissues located in the neck, the thorax, the 
abdomen, the pelvis or in adrenal glands. About 97% of 
neuroblastomas are sympathetic nervous system embryo-
genic malignancies, occurring almost exclusively in the 
newborn and young infants. Unlike germ cell tumors, 
neuroblastomas are the most common cancers in the first 
years of life; its incidence is twice that of leukemia. In many 
cases when it is diagnosed, it has already metastasized to 
the lymphnodes, liver, lungs, bone and bone marrow. The 
neuroblastoma is primarily a tumor of young children. Two 
thirds of neuroblastoma cases are diagnosed in children 
aged below 5 years.15
Another tumor type is the rabdomyossarcoma, 
a malignancy that originates in primitive mesenchymal 
cells, at any site of the body. It is the most common soft 
tissue sarcoma in infancy, and is usually located in the 
head and neck.16
The osteosarcoma is a primary bone malignancy that 
occurs in children, teenagers and young adults. Its peak 
incidence is in the second decade of life; it is about 5% of 
the malignancies in childhood and adolescence.17
Cisplatin ototoxicity and high frequency pure tone 
audiometry
High frequency audiometry has been suggested as 
a method for monitoring the effect of ototoxic drugs on 
hearing.18-20 There are many ototoxic substances - other 
than cisplatin - used for treating a variety of cancers, such 
as carboplatin, actinomycin, bleomycine, nitrogen mustard 
compounds (ex: mustine), misonidazole, vincristine and 
vinblastine.4,9 A study using conventional and high fre-
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quency audiometry assessed 62 individuals treated with 
cisplatin; pre and post testing were done in a time-series 
(each three weeks during therapy and across three months 
post-therapy). Results indicated hearing loss mainly at high 
frequencies due to cisplatin.21 Another study monitored 
cisplatin-treated cancer patients with conventional (250 to 
8,000 Hz) and high frequency audiometry (9,000 to 20,000 
Hz). All patients had normal hearing before cancer therapy. 
Testing was done at each phase of chemotherapy. There 
were point and progressive high frequency alterations; 
after one or two chemotherapy sessions, 100% of patients 
had hearing loss at and above 9,000 Hz. These patients also 
complained of tinnitus and difficulties in understanding 
speech in the presence of background noise.22 This study 
assesses the possible side effects of chemotherapy on the 
hearing of successfully treated cancer patients, considering 
the ototoxic effects of cisplatin and other anticancer drugs. 
The sample included subjects that had cancer that was 
treated with cisplatin and associated drugs during variable 
periods; these subjects had been discharged a few years 
before this study was undertaken. The current study is an 
uncontrolled post-test assessment.
PURPOSE
To assess high frequency auditory thresholds in 
successfully treated cancer patients aged from 5 to 27 ye-
ars, treated with cisplatin and associated drugs, to verify 
possible hearing loss as a sequel of therapy.  
SPECIFIC OBJECTIVES
To assess, in patients treated with cisplatin and 
associations, possible differences in the ototoxic effect 
between the ears that were evaluated, the incidence of 
auditory changes, the number of affected ears at each fre-
quency, the comparison between conventional and high 
frequency audiometry, and the historic variables that might 
have influenced the hearing of these patients.  
MATERIAL AND METHOD
  Participants The sample included volunteers 
who visited a speech therapy clinic located in the city of 
Campinas (Sao Paulo state) after being contacted by tele-
phone from the hospital in which they had been treated 
for cancer. Fifty individuals were contacted, of which 10 
accepted the invitation to participate in this study.
These 10 subjects, of both genders, were aged be-
tween 5 and 27 years at the time data were collected, and 
had started cancer therapy at ages 6 months to 13 years. 
All had been cured at the time this study was done. All had 
been treated with cisplatin, which is ototoxic,1,2,4,5,9 asso-
ciated with other drugs, some of which were also ototoxic. 
An otorhinolaryngologist assessed all participants before 
the research audiological tests were done, as part of the 
method. Other drugs that the subjects had used in cancer 
therapy included doxorubicin, vincristine, actinomycin D, 
cyclophosphamide and etoposide. Of these, vincristine and 
actinomycin D are also ototoxic.4 The attending oncologist 
at the hospital in which the participants had been treated, 
all patients underwent a standard medication protocol 
consisting of giving the drugs jointly in doses that depend 
on the type and extension of the tumor, as well as the 
height and weight of the patients. Thus, all patients had 
been exposed to more than one ototoxic substance simul-
taneously. Participants were characterized according to a 
protocol at the time the clinical history was taken. These 
data are presented on Table 1 (the variable “dose” refers 
to the use of cisplatin and associated drugs).  
Table 1 shows that the time period between che-
motherapy and the audiological testing done in this study 
varied from 3 and a half years and 16 years.
The following was noted about the otological his-
tory: participant 1 reported otitis soon after chemotherapy; 
participant 2 complained of tinnitus, dizziness, hearing loss 
and headaches, but did not report when these symptoms 
started; participant 5 reported bilateral pruritus and hearing 
loss; participant 6 reported tinnitus and pruritus; participant 
7 reported hearing loss; participant 8 reported tinnitus and 
otalgia; participant 10 reported otalgia. Participants 3, 4 
and 9 had no otological complaints.  
Material
A clinical history script for obtaining data about 
participants was written. The following equipment was 
used in audiological testing: a TK otoscope for inspecting 
the external auditory canal. An Interacoustics AC40 Clini-
cal Audiometer with two frequency fields, one at 128 to 
8,000 Hz and the other at 8,000 to 20,000 Hz, according 
to the ANSI S3.6 (1989) and ISO 389 standards. Telepho-
nics TDH 39 P headphones were used for conventional 
audiometry (250 to 8,000 Hz); Koss R/80 headphones 
were used for high frequency audiometry (9,000, 10,000, 
11,200, 12,500, 14,000 e 16,000 Hz). An acoustic booth 
was used. The SAS - system for Windows - V8, was used 
for the analysis of results.   Procedure The Research Ethics 
Committee approved the project and the free informed 
consent form (Protocol 620/05), after which participants 
were informed about the testing procedures to clarify any 
doubts. Patients that agreed to participate signed the free 
informed consent form. The following procedures were 
applied to all patients: 
a) Clinical history taking; 
b) Inspection of the external ear to verify the pre-
sence of ear wax and/or foreign bodies or secretion in the 
external auditory canal that might interfere with testing; 
c) Conventional pure tone audiometry and high 
frequency audiometry, done in an acoustic booth.
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Table 1. Participant data.  
Participant  Current age Gender 
Type of 
tumor    
Type of 
treatment    
Age at 
which tre-
atment was 
started    
Dose
Duration of 
therapy    
Number of 
cycles    
Audiological 
monitoring prior 
to study *
1 5 F
Osteossar-
coma
Chemothe-
rapy    
10 months  780 mg/m² 10 months  
2 cycles 
each week 
and 3 
cycles each 
4 weeks
No
2 19 F
Neuroblas-
toma with 
metastasis
Chemothe-
rapy
13 years    480 mg/m² 2 years    
4 cycles 
each 6 
weeks    
Yes, the year 
before; diagno-
sed with mode-
rate to severe 
sensorineural 
dysacusis
3 8 M
Abdominal 
neuroblas-
tom 
Chemothe-
rapy
6 months 200 mg/m² 6 months
2 cycles 
each 9 
weeks    
No
4 15 F
Rab-
domyos-
sarcoma 
below the 
bladder
Chemothe-
rapy
2 years 400 mg/m2 2 years
4 cycles 
each 21 
days    
No
5 10 F
Abdominal 
germinative 
tumor - yolk 
sac
Chemothe-
rapy
1 year 300 mg/m² 4 months
3 cycles 
each 3 
weeks    
Yes.
Used hearing 
aid 4 years.
6 27 M
Osteossar-
coma    
Chemothe-
rapy
13 years 400 mg/ m² 4 months
4 cycles 
each 6 
weeks    
Yes, two mon-
ths before as 
part of admis-
sion test..
7 11 M
Abdominal 
neuroblas-
toma    
Chemothe-
rapy
1 year 200 mg/m² 1 year
year    2 
cycles each 
9 weeks    
No
8 20 F
Rab-
domyossar-
coma    
Chemothe-
rapy
2 years 360 mg/m2 2 years
4 cycles 
each 3 
weeks    
No
9 22 M
Carcinoma 
of rhino-
pharynx    
Chemothe-
rapy
12 years 480 mg/ m² 2 years
4 cycles 
each 3 
weeks    
Yes, as part of 
admission test
10 19 F
Carcinoma 
of rhino-
pharynx    
Chemo-
therapy + 
Radiothe-
rapy    
8 years 480 mg/m² 2 years
4 cycles 
each 3 
weeks    
Yes, twice (2004 
and 2005), no 
change
* Data provided by participants or caretakers.
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Table 2. Comparison between right and left ears for each tone threshold (in dBNA) that was assessed, as a function of kappa statistics (n=20).
Frequency RE Means LE Means Kappa Weighted kappa Result
0,25 kHz 14 8 01,14 0,47 Different
0,5 kHz 11,5 6 0,11 0,36 Different
1 kHz 14 12 0,41 0,76 No Difference
2 kHz 14,5 11 0,37 0,66 Different
3 kHz 16,5 16,5 0,25 0,79 No Difference
4 kHz 26,5 19 0,42 0,56 Different
6 kHz 49,5 45,5 0,33 0,80 No Difference
8 kHz 47,5 46 0,39 0,78 No Difference
9 kHz 56 56,5 0,38 0,75 No Difference
10 kHz 57 59,5 0,31 0,68 Different
11,2 kHz 56 56 0,29 0,78 No Difference
12,5 kHz 58,5 57,5 0,28 0,74 Different
14 kHz 49,5 49,5 0,04 0,70 Different
16 kHz 45 53 0,51 0,85 No Difference
Table 3. Audiometry results in 10 patients cured of cancer, having used cisplatin chemotherapy.  
PARTICIPANT    RESULTS OF AUDIOMETRY
1 Bilateral symmetrical hearing loss at and above 6,000 Hz
2 Bilateral symmetrical hearing loss at and above 6,000 Hz
3 No hearing loss
4 Non-symmetrical bilateral hearing loss - RE at and above 1,000Hz; LE at and above 10,000 Hz
5 Bilateral symmetric hearing loss at and above 1,000 Hz
6 Bilateral symmetric hearing loss at and above 4,000 Hz
7 Unilateral left hearing loss between 9,000 and 11,200 Hz
8 Bilateral symmetric hearing loss at and above 6,000 Hz
9 No hearing loss
10 Bilateral symmetric hearing loss at and above 6,000 Hz
Table 4. Number of affected ears by auditory frequency
Frequency     Ears 
0,25 kHz 0
0,5 kHz 0
1 kHz 3
2 kHz 3
3 kHz 2
4 kHz 5
6 kHz 13
8 kHz 13
9 kHz 15
10 kHz 15
11,2 kHz 15
12,5 kHz 14
14 kHz 14
16 kHz 14
Table 5. Assessment of the mean duration of chemotherapy, the 
dose and the age (beginning of therapy) for the groups with and 
with no right ear alterations at conventional frequencies
Mean with 
no changes  
Mean with 
alterations  
P Result
Duration of 
chemothera-
pya 
14 meses 16,2 meses 0,417
No 
difference
Dose (mg/m²)  560 457,1 0,167
No 
difference
Age (months)    54 68,28 0,550
No 
difference
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Table 6. Assessment of the mean duration of chemotherapy, the 
dose and the age (beginning of therapy) for the groups with and 
with no left ear alterations at conventional frequencies
Mean with 
no 
changes    
Mean with 
alterations  
P Result
Duration of che-
motherapya 
16,5 
months
15 months 0,714
No 
difference
Dose (mg/m²) 320 466,6 0,330
No 
difference
Age (months)    46,5 75,6 0,186
No 
difference
Table 7. Assessment of the mean duration of chemotherapy, the 
dose and the age (beginning of therapy) for the groups with and 
with no right ear alterations at high frequencies
Mean with 
no 
changes    
Mean with 
alterations  
P Result
Duration of 
chemotherapya 
9 months
17,25 
months
0,089
No 
difference
Dose (mg/m²) 200 460 0,044* Different
Age (months)    9 77,7 0,800
No 
difference
* p < 0,05
Table 8. Assessment of the mean duration of chemotherapy, the 
dose and the age (beginning of therapy) for the groups with and 
with no left ear alterations at high frequencies-
Mean with 
no 
changes    
Mean with 
alterations  
P Result
Duration of che-
motherapya 
6 months
16,6 
months
0,50
No 
difference
Dose (mg/m²) 200 431,1 0,50
No 
difference
Age (months)    6 71,1 1,00
No 
difference
Figure 1. Cumulative curve of affected ears as a function of auditory 
frequency, in kHz.
The descending technique was used for obtaining 
auditory thresholds at 250, 500, 1,000, 2,000, 3,000, 4,000, 
6,000, 8,000, 9,000, 10,000, 11,200, 12,500, 14,000 and 
16,000 Hz (conventional audiometry e high frequency 
audiometry). Threshold testing was started by reducing 
the intensity of the sound stimulus in 10 dB intervals until 
no further response was obtained. Next, the stimulus was 
presented 5 dB above that level and then decreased again 
in 5 dB intervals until no further response was obtained. 
The auditory threshold was considered as the lowest in-
tensity at which a response was obtained.
The procedure was applied to both ears of each 
patient in a single session lasting about 20 minutes. Data 
were treated statistically using different methods, according 
to the aims of this study.
Criteria for establishing the presence of auditory 
alterations In this study, any threshold change higher 
than 25 dBNA in adults and 15 dBNA in children23 for 
conventional pure tone and high frequency audiometry 
confirmed the presence of auditory alterations.  
RESULTS
Comparison between ears
The kappa (k) statistics index was used to check 
possible differences in ototoxicity between ears. This 
statistical test is a measure of agreement used in nominal 
scales for verifying by what amount observations differ 
from expected variations by chance. K statistical values 
range from 0 to 1, where 0 indicates lack of agreement 
beyond chance and 1 is perfect agreement.24 In this study, 
agreement between both ears was sought, as the intention 
was to assess if measurements were similar regardless of 
the tested ear. The interpretation of results is done accor-
ding to k values where 0 indicates poor agreement, over 
0 to 0.20 is slight agreement, 0.21 to 0.40 is moderate 
agreement, 0.41 to 0.60 is considerable agreement, 0.61 
to 0.80 is substantial agreement, and 0.80 to 1 is excellent 
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agreement. Furthermore, the standard error in K statistics 
makes it possible to estimate its statistical significance and 
its 95% confidence interval.24 In this study, a weighted 
kappa coefficient below 0,75 was considered as the cri-
terion for defining the presence of a difference between 
ears. Values closer to 1 indicated that there was more 
evidence showing that both ears responded similarly to 
stimuli. The confidence interval was 95%, but the exact 
estimated value was between the maximum and minimum 
interval value.24
In this study, close frequencies (for example, 8KHz 
and 9KHz) were calculated as different but with less weight 
in weighted k statistics. The weighted k value was conside-
red as evidence of a larger difference between frequency 
categories that are more distant from each other. See Table 
2. There was a significant difference between ears in 50% 
of the 14 frequencies that were assessed, according to 
the weighted kappa; there was no statistically significant 
difference in the other 50% of frequencies.  
Incidence of auditory alterations Eight of 10 parti-
cipants assessed by conventional pure tone audiometry 
and high frequency audiometry presented hearing loss, 
while two had hearing within normal limits for their age, 
according to the criteria described under Method. Table 
3 shows the distribution of cases.
Auditory alterations relative to the affected fre-
quencies
Table 4 and Figure 1 show that in this sample of 
patients treated with ototoxic drugs, including cisplatin, 
ear involvement occurred at and above 1 kHz, and that 
there was marked involvement at and above 6kHz.  
Comparison between the incidence of auditory al-
terations in conventional audiometry and high frequency 
audiometry.
Table 4 and Figure 1 shows that there is a clear 
difference in two sets of data; there is a small group of 
ears that were affected at frequencies up to 4,000 Hz, and 
a larger group of ears that were affected at and above 
4,000 Hz.  
Clinical historic variables that altered the hearing 
of patients
The literature states that cisplatin ototoxicity is di-
rectly related to the dose and the manner by which the 
drug is given.1,2,4 These aspects, therefore, were investi-
gated using Fisher’s exact test according to the following 
variables: age at which chemotherapy was started, the 
duration of therapy, the dose of cisplatin and associated 
drugs, and audiometric results. Fisher’s exact test calculates 
the probability of association or independence between 
the variables that are being analyzed; it establishes the 
probability of an association between variables being 
due to chance. If statistical significance is p ≤ 0.05 in this 
test, then the association between variables is not due to 
chance.25 Findings were treated separately for the right 
and left ears and for conventional pure tone audiometry 
and high frequency audiometry, as shown on Tables 5, 
6, 7 and 8.  
Fisher’s exact test revealed a significant association 
only for the variable dose and the right ear at high fre-
quencies. There was no association between variables in 
the remaining conditions.  
DISCUSSION
Concerning a possible difference in ototoxic action 
between ears, the kappa statistics suggested differences 
between the right and left ears in half of the sample. As to 
the incidence of auditory alterations in the sample, eight 
participants had hearing loss. The data revealed that there 
was significant hearing loss at around 6,000 Hz in 5 cases, 
suggesting that conventional audiometry would be suffi-
cient to diagnose high frequency involvement. Apparently 
in these cases high frequency audiometry would have 
no preventive value, as conventional audiometry would 
provide enough data for justifying preventive measures, 
such as recommending that the patient undergo otorhino-
laryngological and phonoaudiological monitoring due to 
the possibility of progression of hearing loss. Participant 
5 had already started using a hearing aid for four years; 
in this case chemotherapy had ended 3 and a half years 
before starting to use the hearing aid. Hearing loss was 
present at and above 1,000 Hz according to the audiometric 
evaluation; also in this case, high frequency would have 
had no preventive value.
The results of participant 4 deserve further analysis. 
In this case, there was bilateral non-symmetrical hearing 
loss (RE at and above 1,000 Hz and LE at and above 
10,000Hz). Conventional pure tone audiometry (up to 
8,000 Hz) had shown 10 to 15 dBNA in the left ear at all 
frequencies, in other words no loss. High frequency au-
diometry of this ear, however, showed progressive loss; 
it was 35 dBNA at 10,000Hz and showed no response at 
14000 and 16000Hz. In this case, high frequency audio-
metry made it possible to identify the onset of a dege-
nerative process, which would not have been perceived 
in conventional audiometry. In this case, high frequency 
audiometry was effective in detecting a problem, allowing 
preventive monitoring and interventions.
Participant 7 also stood out; there was unilateral left 
hearing loss between 9,000 and 11,200 Hz. Conventional 
audiometry was within normal limits. High frequency au-
diometry made it possible to detect the frequency range in 
which the results were from 20 to 30 dbNA. This was the 
most significant case of the sample, since it was possible to 
detect the onset of high frequency auditory degeneration, 
even though these changes were small from the standpoint 
389
Brazilian Journal of otorhinolaryngology 74 (3) May/June 2008
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
of auditory acuity. In this case, high frequency audiometry 
demonstrates its preventive value; the audiogram suggests 
a trend towards worsening of hearing loss, particularly 
when considering the patient’s age (11 years). Audiolo-
gical information, thus, makes it possible to recommend 
monitoring and possible interventions. Analysis of hearing 
loss at each frequency shows that ears were affected at 
and above 1 kHz, and that there was a marked increase 
in hearing loss at and above 6 kHz. This suggests that in 
this sample, high frequency audiometry could have iden-
tified hearing losses in all 8 participants with hearing loss, 
even if it had been the only test. Confirmation of this is 
seen in the comparison between conventional pure tone 
and high frequency audiometry as applied to this sample. 
Two data sets were clearly identified; one composed of 
ears with losses up to 4,000 Hz and another composed 
of ears with losses at and above this frequency. Thus, 
contrary to what might have been suggested above, high 
frequency audiometry may be considered an important 
tool for detecting and monitoring hearing losses, which 
is in agreement with the literature.18-20
Of all the variables affecting the hearing of patients, 
such as right and left ears, the presence or absence of 
hearing loss, the mean age at which chemotherapy was 
started, the duration of therapy, drug dosages, conven-
tional and high frequency audiometry, only the variable 
drug dose (mg/m2) in the right ear at high frequencies 
was significantly different (P=0.044; p<0.05). This points, 
therefore, to evidence suggesting that the chemotherapy 
drug dosage used by the participants included in our 
sample may have had an important role in causing hea-
ring loss, notwithstanding the time elapsed since the end 
of chemotherapy and this study and the impossibility at 
this point of establishing its effect isolatedly. These results 
are consistent with the literature that was presented at the 
beginning.1,2,4,5,9,18-20  
CONCLUSION
This study aimed to assess high frequency auditory 
thresholds in subjects aged 5 to 27 years that had been 
successfully treated for cancer with cisplatin and associa-
ted drugs to test for possible hearing loss as a sequel of 
therapy. Although the variable drug dose was significantly 
different only for the right ear at high frequencies, it is 
possible that hearing loss detected in 8 of 10 participants 
is due, at least in part, to the ototoxic effect of anticancer 
drugs (cisplatin + vincristine + actinomycin D + associated 
drugs). Such hearing loss may occur slowly and insidiou-
sly, especially because of the drug dose and the duration 
of these substances in the body, even after treatment has 
ceased.4 This study points to the importance of introdu-
cing routine audiological monitoring in chemotherapy for 
cancer patients.  
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